The total sales of inflammatory bowel disease (IBD) drugs are estimated to reach approximately $10.2 billion in the US in 2023, according to analysts. The increase in IBD biologic treatments has been a major driving force in the growth of this market in recent years. In… Read More
Listen to this article on the DDW Podcast: The United Kingdom has established itself as a hub for drug discovery expertise worldwide. Here, DDW’s Megan Thomas highlights the research taking place and where this is happening. The Golden Triangle Though the UK is… Read More
The development of antibodies and associated technologies continues to drive high-value deals, according to a recent report in Nature.1 Using data provided by DealForma for the period 1 January 2022 to 16 June 2023, Nature analysed the deal trends in the field. In 2022,… Read More
A new forecast predicts global prescription drug sales to be worth $1.6tn by 2028. Global biopharmaceutical revenues are forecast to grow at a compounded annual rate of 5.9% to 2028, according to the latest World Preview report published by Evaluate. The annual report forecasts… Read More
Listen to this article on the DDW Podcast: DDW’s Megan Thomas takes a deeper look into why India is ramping up drug discovery research, and explores the country’s innovation hubs of interest. In the global pharmaceuticals market, India ranks third worldwide for production… Read More
The US market for medicines grew by 5% in 2022, reaching a total value of $429Bn on a net price basis. This was driven by a range of factors, including an increase in health services utilisation, which is now back to pre-pandemic levels, and the entry… Read More
The first quarter of 2023 has seen deal flow continue for UK life science and biotech companies at all stages of development, new data from the UK BioIndustry Association and Clarivate shows. As global macro-economic headwinds, suppressed public markets and political uncertainty weighed on investor confidence,… Read More
Listen to this article on the DDW Podcast: DDW’s Megan Thomas takes a snapshot of the US biotech market and some of the ongoing research coming out of the US. In 2021, Savills put together a report on the regional hubs attracting science/pharma investment1. Read More
Could India become an important centre of drug discovery innovation? Diana Spencer explores the evolution of the Hyderabad life sciences hub. India is traditionally known as ‘the pharmacy of the world’ due to its huge pharmaceuticals manufacturing capacity and high quantity of exports, particularly generic medicines… Read More
DDW Editor Reece Armstrong takes a look at Qatar’s drug discovery and life sciences market, exploring how the country is utilising innovative technologies in its approach to healthcare. The Middle East represents one of the world’s most lucrative markets for pharmaceuticals. Along with Africa, the Middle East stands as… Read More
DDW Editor Reece Armstrong explores the Scandinavian drug discovery sector and speaks to key players about Sweden’s place in the market. Scandinavia represents one of the most exciting but perhaps underrepresented markets for the discovery and development of pharmaceuticals. Though not without its challenges, the life sciences industry in Scandinavia… Read More
The top 20 biopharmaceutical companies have recorded a growth of 5.4% in aggregate market capitalisation – from $3.43 trillion on December 31, 2021 to $3.61 trillion on December 31, 2022. According to analytics company GlobalData, 11 companies indicated double-digit growth, with four companies – Merck & Co… Read More
Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment. Therapies that act upon or incorporate RNA to fight disease have… Read More
Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts. In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for… Read More
Myeloma Patients Europe (MPE) has launched an advocacy report on addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE). The report, led by the MPE CEE Workgroup on Access, found huge inequalities for patients, confirming reports from MPE CEE members about a lack… Read More
With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies. … Read More
